Sugi Predict

Sugi Predict / Compounds / SCHEMBL1491247

SCHEMBL1491247

SCHEMBL1491247

C[C@@H](NC(=O)CCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2C P18825 2/20 0.65
▸ SLC6A2 P23975 2/20 0.65
▸ HTR2C P28335 2/20 0.65
▸ SLC6A4 P31645 2/20 0.65
▸ OPRM1 P35372 2/20 0.65
▸ DRD3 P35462 2/20 0.65
▸ CASR P41180 2/20 0.65
▸ HTT P42858 2/20 0.65
▸ MLNR O43193 1/20 0.65
▸ ABCB11 O95342 1/20 0.65
▸ ADRB1 P08588 1/20 0.65
▸ ADORA3 P0DMS8 1/20 0.65
▸ CYP2D6 P10635 1/20 0.65
▸ CHRM1 P11229 1/20 0.65
▸ DRD2 P14416 1/20 0.65
▸ CHRM3 P20309 1/20 0.65
▸ GLRA1 P23415 1/20 0.65
▸ AVPR2 P30518 1/20 0.65
▸ HRH1 P35367 1/20 0.65
▸ MC3R P41968 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8469429 1.00 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL28414827 1.00 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL29761425 1.00 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL1491248 1.00 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL14026866 0.85 ADRA2C (0.53) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL6752551 0.84 LMNA (0.56) LMNAEPHX2GAAMETAP2METAP1
SCHEMBL28476355 0.83 ADRA2C (0.59) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL716961 0.83 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL1580540 0.83 ADRA2C (0.65) ADRA2CSLC6A2HTR2CSLC6A4OPRM1
SCHEMBL17053439 0.81 CASR (0.87) ADRA2CSLC6A2HTR2CSLC6A4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109456201-B Method for asymmetrically synthesizing (R) -cinacalcet 中国农业大学 2020-04-28 — — CN claimed
CN-104592051-B The method preparing N-[1-(R)-(1-naphthyl) ethyl]-3-[3-(trifluoromethyl) phenyl]-1-propionic acid amide. 扬子江药业集团四川海蓉药业有限公司 2016-07-06 — — CN claimed
CN-103739500-B A kind of synthesis of cinacalcet hydrochloride and process for purification SINOPHARM YIXIN PHARMACEUTICAL CO., LTD. (CN) 2016-03-23 — — CN claimed
CN-104592051-A Method for preparing N-(1-(R)-(1-naphthyl)ethyl)-3-(trifluoromethyl)phenyl)-1-propanamide SICHUAN HAIRONG PHARMACEUTICAL CO LTD YANGTZE RIVER PHARMACEUTICAL GROUP 2015-05-06 — — CN claimed
CN-103739500-A Method for synthesizing and refining cinacalcet hydrochlorid SINOPHARM HOLDING YIXIN PHARMACEUTICAL CO LTD 2014-04-23 — — CN claimed
CN-110372492-B Method for synthesizing cinacalcet hydrochloride intermediate by using microchannel reactor 上药康丽（常州）药业有限公司 2022-09-20 — — CN disclosed
CN-112321451-B Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2022-08-23 — — CN disclosed
CN-112321451-B Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2022-08-23 — — CN disclosed
CN-112745226-A Preparation method of cinacalcet hydrochloride and intermediate thereof 上海博志研新药物技术有限公司 2021-05-04 — — CN disclosed
CN-112745226-A Preparation method of cinacalcet hydrochloride and intermediate thereof 上海博志研新药物技术有限公司 2021-05-04 — — CN disclosed
CN-112321451-A Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2021-02-05 — — CN disclosed
CN-112321451-A Method for preparing cinacalcet hydrochloride drug intermediate 福建海西新药创制有限公司 2021-02-05 — — CN disclosed
EP-1990333-A1 Process for the preparation of cinacalcet hydrochloride Sandoz AG (CH) 2008-11-12 — — EP disclosed
US-7449603-B2 Process for the preparation of cinacalcet base TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-11-11 — — US disclosed
US-7449603-B2 Process for the preparation of cinacalcet base TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-11-11 — — US disclosed
WO-2008117299-A1 PROCESS FOR PREPARING CINACALCET HYDROCHLORIDE MACLEODS PHARMACEUTICALS LIMITED (IN) 2008-10-02 — — WO disclosed
WO-2008058235-A2 PROCESSES FOR THE PREPARATION OF CINACALCET DR. REDDY'S LABORATORIES, LTD. (IN) 2008-05-15 — — WO disclosed
WO-2008035381-A2 PROCESS FOR THE PREPARATION OF AMINE DERIVATIVES AS CALCIMIMETICS IND-SWIFT LABORATORIES LIMITED (IN) 2008-03-27 — — WO disclosed
US-20070259964-A1 Process for the preparation of cinacalcet base TEVA PHARMACEUTICALS USA, INC. 2007-11-08 — — US disclosed
US-20070259964-A1 Process for the preparation of cinacalcet base TEVA PHARMACEUTICALS USA, INC. 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259964-A1 Process for the preparation of cinacalcet base KRAS, CA9, CA4 ADRA2C 2222/4885SLC6A2 985/4885HTR2C 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.